Citation

Zacny JP, Paice JA, Coalson DW. Pharmacol. Biochem. Behav. 2011; 100(1): 138-143.

Affiliation

Department of Anesthesia & Critical Care, The University of Chicago, Chicago, IL 60637, USA. jzacny@dacc.uchicago.edu

Copyright

(Copyright © 2011, Elsevier Publishing)

DOI

10.1016/j.pbb.2011.08.011

PMID

21884720

PMCID

PMC3183241

Abstract

Carisoprodol is a centrally acting drug used to relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. There is evidence from different sources that this oral muscle relaxant is abused and that it is associated with impairment leading to arrests for "driving under the influence" as well as increased risk of automobile accidents. Its subjective and psychomotor effects in healthy volunteers at therapeutic and supratherapeutic doses have not been well-characterized, and form the basis of this report. Fifteen healthy volunteers (8 males, 7 females) were administered 0, 350, and 700 mg of carisoprodol in separate sessions and for 6h afterwards they completed a battery of tests at fixed time intervals so as to assess the subjective and psychomotor effects of the drug. The supratherapeutic dose, 700 mg, increased visual analog scale ratings of terms that were more reflective of sedation (e.g., "sleepy," "heavy, sluggish feeling") than those of abuse liability, and produced impaired performance on several psychomotor tests. The therapeutic dose, 350 mg, while producing few and mild subjective effects, still produced psychomotor impairment. The fact that the therapeutic dose of carisoprodol produced minimal subjective effects while adversely affecting performance is of concern in that patients prescribed this drug may feel relatively normal and engage in tasks (driving) that could put themselves and others at risk.

Language: en